Nephrotoxic Exposures and Acute Kidney Injury in Noncritically Ill Children Stratified by Service.


Journal

Hospital pediatrics
ISSN: 2154-1671
Titre abrégé: Hosp Pediatr
Pays: United States
ID NLM: 101585349

Informations de publication

Date de publication:
01 10 2022
Historique:
pubmed: 15 9 2022
medline: 5 10 2022
entrez: 14 9 2022
Statut: ppublish

Résumé

The Nephrotoxic Injury Negated by Just-in-Time Action (NINJA) program is a multicenter, quality improvement initiative that identifies patients at risk for nephrotoxic medication-associated acute kidney injury (NTMx-AKI). The purpose of this study was to (1) evaluate the prevalence and types of NTMx exposures and (2) determine the prevalence of NTMx-AKI categorized by service. Exploratory analysis evaluated potential associations between hospital measures and NTMx-AKI. This is a single-center, retrospective chart review of NTMx exposures from January 2019 to June 2020 in noncritically ill children. High NTMx exposures were defined as ≥3 simultaneous nephrotoxins or ≥3 days of either intravenous vancomycin or aminoglycoside. Prevalence of high NTMx and NTMx-AKI rate were normalized to 1000 patient days. A retrospective case-control analysis assessed for potential associations with development of NTMx-AKI. There were 609 NTMx exposures in 565 patients and 44 (7.2%) episodes of NTMx-AKI. The NTMx prevalence rate per 1000 patient days was highest among liver, neurosurgery, and gastroenterology services. The most commonly used NTMx were vancomycin, intravenous contrast, and nonsteroidal antiinflammatory drugs. The NTMx-AKI rate in exposed patients ranged from 0% to 14% across service lines. AKI was most often attributable to vancomycin. Univariable analyses suggest type and duration of NTMx exposure are associated with development of NTMx-AKI but not with severity. NTMx exposures and NTMx-AKI are variable across services. Partnerships with antimicrobial stewardship and multicenter studies are needed to modify NTMx-AKI risk. Ongoing surveillance is needed in patients who do not have normalization of creatinine before discharge.

Identifiants

pubmed: 36102129
pii: 189492
doi: 10.1542/hpeds.2021-006169
doi:

Substances chimiques

Aminoglycosides 0
Vancomycin 6Q205EH1VU
Creatinine AYI8EX34EU

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

866-877

Informations de copyright

Copyright © 2022 by the American Academy of Pediatrics.

Auteurs

Page E Holsteen (PE)

Department of Pharmacy.

Katja M Gist (KM)

Section of Cardiology, Children's Hospital Colorado, Department of Pediatrics.

John T Brinton (JT)

Department of Biostatistics and Informatics, Colorado School of Public Health.

Maxwell Hebert (M)

Department of Pharmacy.

Melissa Iwanowski (M)

Quality and Patient Safety.

Abby Kim (A)

Department of Pharmacy.

Alexandra Leath (A)

Department of Pharmacy.

Ananya Shah (A)

Heart Institute, Department of Pediatrics, Children's Hospital Colorado, Aurora, Colorado.

Danielle E Soranno (DE)

Department of Pediatrics, Section of Nephrology, University of Colorado, Aurora, Colorado.

Magda N Marschner (MN)

Department of Pharmacy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH